Stem cell mobilization and collection from pediatric patients and healthy children

KARAKÜKCÜ M., ÜNAL E.

TRANSFUSION AND APHERESIS SCIENCE, cilt.53, sa.1, ss.17-22, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 53 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.transci.2015.05.010
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.17-22
  • Anahtar Kelimeler: Hematopoietic stem cell transplantation, Hematopoietic stem cell mobilization, Hematopoietic stem cell collection, Pediatric donors, Children, COLONY-STIMULATING FACTOR, DISEASES WORKING PARTY, BLOOD PROGENITOR CELLS, VERSUS-HOST-DISEASE, PRIMED BONE-MARROW, PLUS G-CSF, PERIPHERAL-BLOOD, ALLOGENEIC TRANSPLANTATION, AUTOLOGOUS TRANSPLANTATION, SAFETY CONSIDERATIONS
  • Erciyes Üniversitesi Adresli: Evet

Özet

Today, hematopoietic stem cell transplantation (HSCT) is a standard treatment for a variety of conditions in children, including certain malignancies, hemoglobinopathies, bone marrow failure syndromes, immunodeficiency and inborn metabolic disease. Two fundamentally different types of HSCT are categorized by the source of the stem cells. The first, autologous HSCT represents infusion of patient's own hematopoietic stem cells (HSCs) obtained from the patient; the second, allogeneic HSCT refers to the infusion of HSCs obtained from a donor via bone marrow harvest or apheresis. Bone marrow has been the typical source for HSCs for pediatric donors. Bone marrow harvest is a safe procedure mainly related to mild and transient side effects. Recently, a dramatically increased use of mobilized peripheral blood stem cells (PBSCs) in the autologous as well as allogeneic setting has been seen worldwide. There are limited data comparing mobilization regimens; also mobilization practices vary widely in children. The most commonly used approach includes granulocyte colony stimulating factor (G-CSF) at 10 mg/kg/day as a single daily dose for 4 days before the day of leukapheresis. G-CSF induced pain was less reported in children compared to adult donors. For the collection, there are several technical problems, derived from the size of the patient or donor, which must be considered before and during the apheresis. Vascular access, extracorporeal circuit volume, blood flow rates are the main limiting factors for PBSC collection in small children. Most children younger than 12 years require central vascular access for apheresis; line placement may require either general anesthesia or conscious sedation and many of the complications arise from the central venous catheter. In this review, we discuss that the ethical considerations and some principals regarding children serving as stem cell donors and the commonest sources of HSCs are presented in children, together with a discussion of how to collect and process these cells. (C) 2015 Elsevier Ltd. All rights reserved,